Global Search | Novartis

Hide Filters

Showing 2745 results

Press release / Sep 01, 2021

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)

Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three…
Press release / Aug 30, 2021

Novartis Leqvio®* (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD

Separate post hoc analyses of pooled Phase III ORION-9, -10 and -11 data show twice-yearly** Leqvio® (inclisiran) consistently reduced low-density lipoprotein cholesterol (LDL-C) in patients with…
Press release / Aug 30, 2021

Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO

New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety…
Press release / Oct 07, 2021

Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis

Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)Novartis will be commencing Phase III…
Press release / Oct 01, 2021

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz,…
Press release / Sep 30, 2021

Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria

Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile…
Press release / Sep 30, 2021

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and…
Press release / Sep 29, 2021

Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria

Novartis and Medicines for Malaria Venture (MMV) report positive Phase 2b study results for novel non-artemisinin combination to treat uncomplicated malariaIn the Phase 2b study conducted in children…
Press release / Sep 29, 2021

New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis

New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
Press release / Sep 29, 2021

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life, as reported by patients

Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…